Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation

Volume: 18, Issue: 10, Pages: 1501 - 1512
Published: Jun 28, 2021
Abstract
The FDA approval of oral semaglutide for type 2 diabetes (2019) and oral octreotide for acromegaly (2020) is evidence that selected niche peptides can be administered orally if formulated with selected intestinal permeation enhancers.We evaluated the oral octreotide formulation, MYCAPSSA® (Chiasma Pharmaceuticals, Needham, MA, USA). An outline of the current standard of care in acromegaly and the benefits of oral octreotide versus depot...
Paper Details
Title
Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation
Published Date
Jun 28, 2021
Volume
18
Issue
10
Pages
1501 - 1512
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.